Akari Therapeutics Plc EV/EBIT
What is the EV/EBIT of Akari Therapeutics Plc?
The EV/EBIT of Akari Therapeutics Plc is N/A
What is the definition of EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT of companies in the Health Care sector on NASDAQ compared to Akari Therapeutics Plc
What does Akari Therapeutics Plc do?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Companies with ev/ebit similar to Akari Therapeutics Plc
- Canadian General Investments has EV/EBIT of N/A
- Omnia Metals Ltd has EV/EBIT of N/A
- Netgear Inc has EV/EBIT of N/A
- Vroom has EV/EBIT of N/A
- OncoSec Medical Inc has EV/EBIT of N/A
- Hemogenyx Pharmaceuticals Plc has EV/EBIT of N/A
- Akari Therapeutics Plc has EV/EBIT of N/A
- Youngevity International Inc has EV/EBIT of N/A
- Sigma Labs Inc has EV/EBIT of N/A
- GOLO Mobile has EV/EBIT of N/A
- NeuroOne Medical Technologies has EV/EBIT of N/A
- Vision Marine Technologies has EV/EBIT of N/A
- Medicenna Therapeutics has EV/EBIT of N/A